OLD Category: Oncology

Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas

• Angerilli V, Fontana E, Lonardi S...Loupakis F, Valeri N, Fassan M

Systematic review of the immunological landscape of Wilms tumors

• Palmisani F, Kovar H, Kager L, Amann G, Metzelder M, Bergmann M

Molecular Mechanisms of Antiproliferative and Apoptosis Activity by 1,5-Bis(4-Hydroxy-3-Methoxyphenyl)1,4-Pentadiene-3-one (MS13) on Human Non-Small Cell Lung Cancer Cells

• Wan Mohd Tajuddin WNB, Abas F, Othman I, Naidu R

Prolonged cadmium exposure alters benign uterine fibroid cell behavior, extracellular matrix components, and TGFB signaling

• Yan Y, Liu J, Lawrence A, Dykstra MJ, Fannin R, Gerrish K, Tucker CJ, Scappini E, Dixon D

Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials

• Dahl M, Husby S, Eskelund CW...Kjems J, Kristensen LS, Gronbaek K

The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade

• Hildebrand KM, Singla AK, McNeil R...Mahoney DJ, Jirik FR, Monument MJ

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study

• Strati P, de Vos S, Ruan J...Frigault MM, Calvo R, Dyer MJ

miR-138-5p induces aggressive traits by targeting Trp53 expression in murine melanoma cells, and correlates with poor prognosis of melanoma patients

• da Cruz AT, Hunger A, de Melo FHM...Strauss BE, Tron V, Jasiulionis MG

Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study

• Bartlett JMS, Bayani J, Kornaga E...van de Velde CJH, Stein RC, Rea D

Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing

• Wolfson B, Padget MR, Schlom J, Hodge JW

Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients treated with immune checkpoint inhibitors

• Kim H, Kwon HJ, Kim ES, Kwon S, Suh KJ, Kim SH, Kim YJ, Lee JS, Chung JH

SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy

• Ji X, Liu Y, Mei F, Li X, Zhang M, Yao B, Wu R, You J, Pei F